|Bid||9.53 x 3200|
|Ask||10.97 x 800|
|Day's Range||10.15 - 10.52|
|52 Week Range||4.65 - 10.52|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.17|
Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to seven individuals entering into employment with Fluidigm. In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 48,900 restricted stock units (RSU Awards).
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In December 2018, Fluidigm Corporation (NASDAQ:FLDM) announcedRead More...
Fluidigm (FLDM) delivered earnings and revenue surprises of 70.00% and 5.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 36 cents per share. Losses, adjusted for one-time gains and costs, were 6 cents per share. The company that makes equipment to control ...
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and.
Fluidigm Corporation (FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of T cell-driven immune-mediated inflammatory diseases (IMIDs). The research will potentially empower more precise treatments using existing drugs and identify new targets for future drug development.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of.
NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Jan. 14, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report.
SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing.
Does Fluidigm Corporation (NASDAQ:FLDM) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. The shares include 1,222,500 shares of common stock sold pursuant to an over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.
Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,222,500 shares of common stock at the public offering price. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies. The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.